Divi's Laboratories Ltd
NSE:DIVISLAB

Watchlist Manager
Divi's Laboratories Ltd Logo
Divi's Laboratories Ltd
NSE:DIVISLAB
Watchlist
Price: 5 886.75 INR 1.81% Market Closed
Market Cap: 1.6T INR
Have any thoughts about
Divi's Laboratories Ltd?
Write Note

Gross Margin
Divi's Laboratories Ltd

59.8%
Current
62%
Average
44%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
59.8%
=
Gross Profit
48.9B
/
Revenue
81.9B

Gross Margin Across Competitors

Country IN
Market Cap 1.6T INR
Gross Margin
60%
Country US
Market Cap 1.2T USD
Gross Margin
55%
Country US
Market Cap 201B USD
Gross Margin
41%
Country US
Market Cap 166.8B USD
Gross Margin
60%
Country KR
Market Cap 66.7T KRW
Gross Margin
49%
Country CH
Market Cap 38.4B CHF
Gross Margin
29%
Country US
Market Cap 38.7B USD
Gross Margin
55%
Country US
Market Cap 36.3B USD
Gross Margin
35%
Country US
Market Cap 27B USD
Gross Margin
59%
Country US
Market Cap 24.1B USD
Gross Margin
35%
Country US
Market Cap 22.2B USD
Gross Margin
60%
No Stocks Found

Divi's Laboratories Ltd
Glance View

Market Cap
1.6T INR
Industry
Life Sciences Tools & Services

Divi's Laboratories Ltd. has carved an enviable niche for itself in the global pharmaceutical industry, with its origins tracing back to 1990 in Hyderabad, India. With a steadfast focus on research and development, the company stands as a formidable force in the Active Pharmaceutical Ingredients (APIs) and Intermediates manufacturing sector. Its strategy hinges on two complementary business segments: generic APIs and custom synthesis of APIs and intermediates. By catering to a broad spectrum of therapeutic areas, from cardiovascular ailments to pain management, Divi's capitalizes on economies of scale and technological innovation to produce cost-effective, high-quality pharmaceutical products. This strategy not only aligns with the company’s expertise in process development and chemical synthesis but also positions it as a key supplier to major pharmaceutical companies worldwide, providing a significant portion of their API requirements. The crux of Divi's financial engine lies in its custom synthesis segment, where it forms strategic alliances with global pharmaceutical giants, offering end-to-end solutions from drug discovery to commercialization. This vertical is fueled by long-term contracts that bolster the company’s revenue visibility and profitability. Meanwhile, the generic APIs segment benefits from the rising global demand for affordable healthcare solutions, particularly in emerging markets. Divi’s Laboratories leverages its state-of-the-art manufacturing facilities, which are compliant with international regulatory standards, to ensure efficient production cycles and maintain a consistent supply chain. Through its blend of innovative R&D, a robust manufacturing backbone, and strategic partnerships, Divi's Laboratories adeptly navigates the complexities of the pharmaceutical industry, making it a stalwart in the sector's supply chain ecosystem.

DIVISLAB Intrinsic Value
3 256.64 INR
Overvaluation 45%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
59.8%
=
Gross Profit
48.9B
/
Revenue
81.9B
What is the Gross Margin of Divi's Laboratories Ltd?

Based on Divi's Laboratories Ltd's most recent financial statements, the company has Gross Margin of 59.8%.